Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β

Bibiana Bielekova; Nancy Richert; Thomas Howard; Gregg Blevins; Silva Markovic-Plese; Jennifer McCartin; Jens Würfel; Joan Ohayon; Thomas A. Waldmann; Henry F. McFarland; Roland Martin

doi:10.1073/pnas.0402653101

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β

Bibiana Bielekova, Nancy Richert, Thomas Howard, Gregg Blevins, Silva Markovic-Plese, Jennifer McCartin, Jens Würfel, Joan Ohayon, Thomas A. Waldmann, Henry F. McFarland, Roland Martin

Research output: Contribution to journal › Article › peer-review

279 Scopus citations

Abstract

Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-β therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.

Original language	English (US)
Pages (from-to)	8705-8708
Number of pages	4
Journal	Proceedings of the National Academy of Sciences of the United States of America
Volume	101
Issue number	23
DOIs	https://doi.org/10.1073/pnas.0402653101
State	Published - Jun 8 2004
Externally published	Yes

ASJC Scopus subject areas

Genetics
General

Access to Document

10.1073/pnas.0402653101

Cite this

Bielekova, B., Richert, N., Howard, T., Blevins, G., Markovic-Plese, S., McCartin, J., Würfel, J., Ohayon, J., Waldmann, T. A., McFarland, H. F., & Martin, R. (2004). Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β. Proceedings of the National Academy of Sciences of the United States of America, 101(23), 8705-8708. https://doi.org/10.1073/pnas.0402653101

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β. / Bielekova, Bibiana; Richert, Nancy; Howard, Thomas et al.
In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 23, 08.06.2004, p. 8705-8708.

Research output: Contribution to journal › Article › peer-review

Bielekova, B, Richert, N, Howard, T, Blevins, G, Markovic-Plese, S, McCartin, J, Würfel, J, Ohayon, J, Waldmann, TA, McFarland, HF & Martin, R 2004, 'Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β', Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 23, pp. 8705-8708. https://doi.org/10.1073/pnas.0402653101

@article{19d130fa685f4f31afede8a24a8feb03,

title = "Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β",

abstract = "Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-β therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.",

author = "Bibiana Bielekova and Nancy Richert and Thomas Howard and Gregg Blevins and Silva Markovic-Plese and Jennifer McCartin and Jens W{\"u}rfel and Joan Ohayon and Waldmann, {Thomas A.} and McFarland, {Henry F.} and Roland Martin",

year = "2004",

month = jun,

day = "8",

doi = "10.1073/pnas.0402653101",

language = "English (US)",

volume = "101",

pages = "8705--8708",

journal = "Proceedings of the National Academy of Sciences of the United States of America",

issn = "0027-8424",

publisher = "National Academy of Sciences",

number = "23",

}

TY - JOUR

T1 - Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β

AU - Bielekova, Bibiana

AU - Richert, Nancy

AU - Howard, Thomas

AU - Blevins, Gregg

AU - Markovic-Plese, Silva

AU - McCartin, Jennifer

AU - Würfel, Jens

AU - Ohayon, Joan

AU - Waldmann, Thomas A.

AU - McFarland, Henry F.

AU - Martin, Roland

PY - 2004/6/8

Y1 - 2004/6/8

N2 - Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-β therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.

AB - Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-β therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.

UR - http://www.scopus.com/inward/record.url?scp=2942537826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942537826&partnerID=8YFLogxK

U2 - 10.1073/pnas.0402653101

DO - 10.1073/pnas.0402653101

M3 - Article

C2 - 15161974

AN - SCOPUS:2942537826

SN - 0027-8424

VL - 101

SP - 8705

EP - 8708

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

IS - 23

ER -

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this